Skip to content

Alligator Bioscience

  •  
    • Se
  • Startpage
  • About Alligator
    • Board of Directors
    • Senior Management
    • Career
  • Research and development
    • Immunotherapy of cancer
    • Pipeline
      • Mitazalimab
      • Neo-X-PrimeTM
      • ALG.APV-527
      • ATOR-1017
      • Research projects
    • Scientific publications
    • Technology platform
      • Alligator-GOLD®
      • Alligator-FABTM
      • FIND®
    • Scientific advisors
  • Corporate governance
    • General meeting
    • Board of Directors and Management
    • Nomination Committee
    • Audit Committee
    • Remuneration Committee
    • Remuneration
    • Auditors
    • Articles of association
    • Internal control
  • Investors
    • Share and owner information
    • Sharegraph
    • Analysts
    • Preferential Rights Issue Q2 2023
    • Preferential Rights Issue Q4 2021
    • Preferential Rights Issue Q1 2021
    • IPO
    • Financial reports
      • Interim reports
      • Year End Reports
      • Annual reports
    • Financial calendar
    • Presentations
  • Business Development
  • News
  • Press releases
  • Contact
  • Events

  1. Startpage
  2. News
  3. IR
Key downloads
Alligator Bioscience AB reports financial results for the first 9 months of 2023 and for Q3 2023 and provides a business updateAlligator Bioscience AB reports financial results for H1 2023 and Q2 2023 and provides a business updateBulletin from the annual general meeting in Alligator Bioscience AB on 26 May 2023Alligator Bioscience AB reports financial results for Q1 2023 and provides a business updateBulletin from the extraordinary general meeting in Alligator Bioscience AB
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
All IRRegulatoryReport
View as grid View as list
2023-11-09

Alligator Bioscience to Participate in Upcoming Industry Conferences in November 2023

Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that senior company representatives will participate in the fo ...
Continue reading
2023-11-06
Regulatory

Correction: Nomination Committee appointed in respect of AGM 2024 in Alligator Bioscience AB

The press release as of November 6, 2023 regarding the Nomination Committee appointed in respect of AGM 2024 incorrectly stated Hans-Peter O ...
Continue reading
2023-11-06
Regulatory

Nomination Committee appointed in respect of AGM 2024 in Alligator Bioscience AB

Lund, Sweden, November 6, 2023– Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that the Nomination Committee in preparation ...
Continue reading
2023-11-03

Alligator Bioscience Announces Poster Presentation on Neo-X-Prime Bispecific Antibody ATOR-4066 at SITC Annual Meeting 2023

Presentation highlights ATOR-4066's superior anti-tumor effect and confirms CEACAM5-conditional activation of CD40 expressing cells Dat ...
Continue reading
2023-10-31

Alligator Bioscience Announces Capital Markets Day 2023

Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces it will hold a Capital Markets Day on December 1, 2023. ...
Continue reading
2023-10-26
Regulatory

Alligator Bioscience AB reports financial results for the first 9 months of 2023 and for Q3 2023 and provides a business update

European Medicines Agency grants mitazalimab Orphan Designation in pancreatic cancer Technical Feasibility achieved in second collaboration ...
Continue reading
2023-10-12

Alligator Bioscience Granted New Composition of Matter Patent in Europe for Mitazalimab

New patent expands protection for mitazalimab in Europe Patent protects composition of matter for mitazalimab until 2038 (including potentia ...
Continue reading
2023-10-05

Alligator Bioscience Announces Publication Highlighting ATOR-1017 Preclinical Data in the Scientific Journal “Cancer Immunology, Immunotherapy”

ATOR-1017, a potential best-in-class 4-1BB monoclonal antibody, demonstrates an excellent preclinical profile with a unique binding site on ...
Continue reading
2023-10-03

Alligator Bioscience to Participate in Upcoming Industry Conferences in October 2023

Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that senior company representatives will participate in the fo ...
Continue reading

Posts navigation

Older posts
  1. Startpage
  2. News
  3. IR
About Alligator

Alligator develops antibody-based pharmaceuticals for cancer treatment. The company specializes in the development of tumor-directed immunotherapies, in particular agonistic mono- and bispecific antibodies. The company is active in the early stages of drug development, from idea to clinical phase 2 studies and beyond.

Alligator Bioscience has global headquarters in Lund, Sweden, and is listed on Nasdaq Stockholm (ticker: ATORX).

Links
  • About Alligator
  • R&D
  • Corporate governance
  • Investors
  • News
  • Business Development
  • Privacy Policy
Contact us

Headquarter
Alligator Bioscience AB
Medicon Village
Scheelevägen 2
SE-223 81 Lund Sweden

Satellite office
Alligator Bioscience AB
Forskaren
Scheelevägen 22
SE-223 63 Lund
Sweden

Phone:
+ 46 (0)46 540 82 00

info@alligatorbioscience.com
ir@alligatorbioscience.com
bd@alligatorbioscience.com

Follow us

  

Email subscription

Subscribe to get our pressreleases and investor alerts by email from Alligator Bioscience.

Subscribe

  • © Copyright 2019 – Alligator Bioscience AB

  • Privacy Policy | Use of Cookies |  Change your cookie settings here.

  • Disclaimer Market data could be delayed. Delivered by Modular Finance.

Cookies
We use cookies for administering, monitoring and optimizing the website, and for analytical purposes, in accordance with what is stated in our cookie policy.
Settings Accept all
Cookies
Do your settings below. Or read our cookie policy.
  • Necessary
    These cookies are not optional. They are needed for the website to function.
  • Statistics
    In order for us to improve the website's functionality and structure, based on how the website is used.
  • Experience
    In order for our website to perform as well as possible during your visit. If you refuse these cookies, some functionality will disappear from the website.
  • Marketing
    By sharing your interests and behavior as you visit our site, you increase the chance of seeing personalized content and offers.
Save Accept all